Twist, a novel oncogene, is upregulated in pancreatic cancer: Clinical implication of Twist expression in pancreatic juice

Kenoki Ohuchida, Kazuhiro Mizumoto, Seiji Ohhashi, Hiroshi Yamaguchi, Hiroyuki Konomi, Eishi Nagai, Koji Yamaguchi, Masazumi Tsuneyoshi, Masao Tanaka

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Despite evidence that Twist, a highly conserved basic helix-loop-helix transcription factor, is a novel oncogene, there are no reports describing Twist expression in pancreatic cancer. Intraductal papillary mucinous neoplasm (IPMN) and pancreatic intraepithelial neoplasia (PanIN) are precursor lesions of pancreatic cancer. To clarify involvement of Twist expression in pancreatic cancer, we used quantitative reverse transcription-polymerase chain reaction and examined Twist expression in pancreatic cancer, IPMN, and non-neoplastic pancreas using bulk tissues (11 cancers, 18 IPMNs, and 15 non-neoplastic pancreata), microdissected cells (cancer from 22 sections, IPMN from 19 sections, PanIN from 6 sections, and pancreatitis-affected epithelial cells from 14 sections), and pancreatic juice (16 from cancer, 28 from IPMN, and 17 from pancreatitis). Twist expression differed significantly between cancer and IPMN bulk tissues (p < 0.0001) but not between cancer and non-neoplastic tissues. Twist expressions differed significantly between microdissected cancer cells, IPMN cells, and pancreatitis-affected cells (all comparisons, p < 0.017). PanIN cells expressed significantly lower levels of Twist than did IDC cells (p = 0.016). Twist expression differed significantly between cancer and IPMN juice samples (p = 0.0002) but not between cancer and pancreatitis juice samples. Receiver operation characteristic curve analyses revealed that measurement of Twist was more useful for discriminating cancer from IPMN than from chronic pancreatitis (p = 0.009). Our results suggest that Twist is involved in tumor progression of pancreatic cancer and that measurement of Twist in pancreatic juice may be useful to differentiate pancreatic cancer from nonmalignant neoplasms such as IPMN.

Original languageEnglish
Pages (from-to)1634-1640
Number of pages7
JournalInternational Journal of Cancer
Volume120
Issue number8
DOIs
Publication statusPublished - Apr 15 2007

Fingerprint

Pancreatic Juice
Pancreatic Neoplasms
Oncogenes
Neoplasms
Pancreatitis
Pancreas

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Twist, a novel oncogene, is upregulated in pancreatic cancer : Clinical implication of Twist expression in pancreatic juice. / Ohuchida, Kenoki; Mizumoto, Kazuhiro; Ohhashi, Seiji; Yamaguchi, Hiroshi; Konomi, Hiroyuki; Nagai, Eishi; Yamaguchi, Koji; Tsuneyoshi, Masazumi; Tanaka, Masao.

In: International Journal of Cancer, Vol. 120, No. 8, 15.04.2007, p. 1634-1640.

Research output: Contribution to journalArticle

Ohuchida, Kenoki ; Mizumoto, Kazuhiro ; Ohhashi, Seiji ; Yamaguchi, Hiroshi ; Konomi, Hiroyuki ; Nagai, Eishi ; Yamaguchi, Koji ; Tsuneyoshi, Masazumi ; Tanaka, Masao. / Twist, a novel oncogene, is upregulated in pancreatic cancer : Clinical implication of Twist expression in pancreatic juice. In: International Journal of Cancer. 2007 ; Vol. 120, No. 8. pp. 1634-1640.
@article{28ed41668e2a4cd398cb4970fb19d498,
title = "Twist, a novel oncogene, is upregulated in pancreatic cancer: Clinical implication of Twist expression in pancreatic juice",
abstract = "Despite evidence that Twist, a highly conserved basic helix-loop-helix transcription factor, is a novel oncogene, there are no reports describing Twist expression in pancreatic cancer. Intraductal papillary mucinous neoplasm (IPMN) and pancreatic intraepithelial neoplasia (PanIN) are precursor lesions of pancreatic cancer. To clarify involvement of Twist expression in pancreatic cancer, we used quantitative reverse transcription-polymerase chain reaction and examined Twist expression in pancreatic cancer, IPMN, and non-neoplastic pancreas using bulk tissues (11 cancers, 18 IPMNs, and 15 non-neoplastic pancreata), microdissected cells (cancer from 22 sections, IPMN from 19 sections, PanIN from 6 sections, and pancreatitis-affected epithelial cells from 14 sections), and pancreatic juice (16 from cancer, 28 from IPMN, and 17 from pancreatitis). Twist expression differed significantly between cancer and IPMN bulk tissues (p < 0.0001) but not between cancer and non-neoplastic tissues. Twist expressions differed significantly between microdissected cancer cells, IPMN cells, and pancreatitis-affected cells (all comparisons, p < 0.017). PanIN cells expressed significantly lower levels of Twist than did IDC cells (p = 0.016). Twist expression differed significantly between cancer and IPMN juice samples (p = 0.0002) but not between cancer and pancreatitis juice samples. Receiver operation characteristic curve analyses revealed that measurement of Twist was more useful for discriminating cancer from IPMN than from chronic pancreatitis (p = 0.009). Our results suggest that Twist is involved in tumor progression of pancreatic cancer and that measurement of Twist in pancreatic juice may be useful to differentiate pancreatic cancer from nonmalignant neoplasms such as IPMN.",
author = "Kenoki Ohuchida and Kazuhiro Mizumoto and Seiji Ohhashi and Hiroshi Yamaguchi and Hiroyuki Konomi and Eishi Nagai and Koji Yamaguchi and Masazumi Tsuneyoshi and Masao Tanaka",
year = "2007",
month = "4",
day = "15",
doi = "10.1002/ijc.22295",
language = "English",
volume = "120",
pages = "1634--1640",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "8",

}

TY - JOUR

T1 - Twist, a novel oncogene, is upregulated in pancreatic cancer

T2 - Clinical implication of Twist expression in pancreatic juice

AU - Ohuchida, Kenoki

AU - Mizumoto, Kazuhiro

AU - Ohhashi, Seiji

AU - Yamaguchi, Hiroshi

AU - Konomi, Hiroyuki

AU - Nagai, Eishi

AU - Yamaguchi, Koji

AU - Tsuneyoshi, Masazumi

AU - Tanaka, Masao

PY - 2007/4/15

Y1 - 2007/4/15

N2 - Despite evidence that Twist, a highly conserved basic helix-loop-helix transcription factor, is a novel oncogene, there are no reports describing Twist expression in pancreatic cancer. Intraductal papillary mucinous neoplasm (IPMN) and pancreatic intraepithelial neoplasia (PanIN) are precursor lesions of pancreatic cancer. To clarify involvement of Twist expression in pancreatic cancer, we used quantitative reverse transcription-polymerase chain reaction and examined Twist expression in pancreatic cancer, IPMN, and non-neoplastic pancreas using bulk tissues (11 cancers, 18 IPMNs, and 15 non-neoplastic pancreata), microdissected cells (cancer from 22 sections, IPMN from 19 sections, PanIN from 6 sections, and pancreatitis-affected epithelial cells from 14 sections), and pancreatic juice (16 from cancer, 28 from IPMN, and 17 from pancreatitis). Twist expression differed significantly between cancer and IPMN bulk tissues (p < 0.0001) but not between cancer and non-neoplastic tissues. Twist expressions differed significantly between microdissected cancer cells, IPMN cells, and pancreatitis-affected cells (all comparisons, p < 0.017). PanIN cells expressed significantly lower levels of Twist than did IDC cells (p = 0.016). Twist expression differed significantly between cancer and IPMN juice samples (p = 0.0002) but not between cancer and pancreatitis juice samples. Receiver operation characteristic curve analyses revealed that measurement of Twist was more useful for discriminating cancer from IPMN than from chronic pancreatitis (p = 0.009). Our results suggest that Twist is involved in tumor progression of pancreatic cancer and that measurement of Twist in pancreatic juice may be useful to differentiate pancreatic cancer from nonmalignant neoplasms such as IPMN.

AB - Despite evidence that Twist, a highly conserved basic helix-loop-helix transcription factor, is a novel oncogene, there are no reports describing Twist expression in pancreatic cancer. Intraductal papillary mucinous neoplasm (IPMN) and pancreatic intraepithelial neoplasia (PanIN) are precursor lesions of pancreatic cancer. To clarify involvement of Twist expression in pancreatic cancer, we used quantitative reverse transcription-polymerase chain reaction and examined Twist expression in pancreatic cancer, IPMN, and non-neoplastic pancreas using bulk tissues (11 cancers, 18 IPMNs, and 15 non-neoplastic pancreata), microdissected cells (cancer from 22 sections, IPMN from 19 sections, PanIN from 6 sections, and pancreatitis-affected epithelial cells from 14 sections), and pancreatic juice (16 from cancer, 28 from IPMN, and 17 from pancreatitis). Twist expression differed significantly between cancer and IPMN bulk tissues (p < 0.0001) but not between cancer and non-neoplastic tissues. Twist expressions differed significantly between microdissected cancer cells, IPMN cells, and pancreatitis-affected cells (all comparisons, p < 0.017). PanIN cells expressed significantly lower levels of Twist than did IDC cells (p = 0.016). Twist expression differed significantly between cancer and IPMN juice samples (p = 0.0002) but not between cancer and pancreatitis juice samples. Receiver operation characteristic curve analyses revealed that measurement of Twist was more useful for discriminating cancer from IPMN than from chronic pancreatitis (p = 0.009). Our results suggest that Twist is involved in tumor progression of pancreatic cancer and that measurement of Twist in pancreatic juice may be useful to differentiate pancreatic cancer from nonmalignant neoplasms such as IPMN.

UR - http://www.scopus.com/inward/record.url?scp=33947142478&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947142478&partnerID=8YFLogxK

U2 - 10.1002/ijc.22295

DO - 10.1002/ijc.22295

M3 - Article

C2 - 17236203

AN - SCOPUS:33947142478

VL - 120

SP - 1634

EP - 1640

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 8

ER -